ArticleCancers2026

Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers.

Qi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.